EVNIN LUKE sold $45K of HOWL (indirect holdings)
EVNIN LUKE sold 143,199 indirectly-held shares of Werewolf Therapeutics, Inc. (HOWL) at an average of $0.31 ($0.31–$0.32) across 2 trades over 2026-07-06 to 2026-07-07 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market sale details (143,199 shares at $0.3100 to $0.3200) and post-sale holdings of 0 shares under a 10b5-1 plan.
Market read
This provides incremental sentiment information (insider selling) but is unlikely to drive a fundamental repricing without additional company news.
What to watch
Because the sale is indirect and pre-arranged, traders should focus on whether there are concurrent operational catalysts (trial updates, financing, partnerships) rather than the sale itself.
Background
The article is an SEC Form 4 insider transaction disclosure for Werewolf Therapeutics, Inc.
Ticker impact
Werewolf Therapeutics director EVNIN LUKE sold $44.7K of HOWL via a 10b5-1 plan, leaving 0 shares after the trades.
Likely minimal price impact; any reaction should fade unless accompanied by other company-specific news.
The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the disclosed sale size is modest relative to typical market moves.
Market effects
No clear sector read-through from a small, 10b5-1 director sale.
None indicated.
None indicated.
Counterpoint
A 10b5-1 sale can still coincide with internal liquidity needs or portfolio rebalancing, so it should not be over-interpreted as bearish.
Key entities
- issuerWerewolf Therapeutics, Inc.
Subject of the Form 4 insider transaction disclosure (HOWL).
- insiderEVNIN LUKE
Director who sold HOWL shares via a pre-arranged 10b5-1 plan.
